Immunotherapy approaches for malignant pleural mesothelioma
Nature Reviews Clinical Oncology, Published online: 01 July 2022; doi:10.1038/s41571-022-00649-7After a frustratingly slow pace of development of new effective treatments for mesothelioma, single or dual therapy with immune-checkpoint inhibitors has substantially improved overall survival over previous standard-of-care therapies in various disease settings. The authors of this Review summarize the current evidence on immunotherapies for mesothelioma, focusing on strategies evaluated in randomized clinical trials and emerging predictors of response, and discuss future treatment opportunities. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 1, 2022 Category: Cancer & Oncology Authors: Dean A. Fennell Sean Dulloo James Harber Source Type: research
AKT inhibition associated with improved OS
Nature Reviews Clinical Oncology, Published online: 01 July 2022; doi:10.1038/s41571-022-00662-wAKT inhibition associated with improved OS (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 1, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
T-DXd active in HER2-low disease
Nature Reviews Clinical Oncology, Published online: 01 July 2022; doi:10.1038/s41571-022-00663-9T-DXd active in HER2-low disease (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - July 1, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
SHINE a light: frontline ibrutinib for MCL
Nature Reviews Clinical Oncology, Published online: 24 June 2022; doi:10.1038/s41571-022-00658-6SHINE a light: frontline ibrutinib for MCL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 24, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
ctDNA guides omission of adjuvant chemotherapy for stage II CRC
Nature Reviews Clinical Oncology, Published online: 24 June 2022; doi:10.1038/s41571-022-00657-7ctDNA guides omission of adjuvant chemotherapy for stage II CRC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 24, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
HSP90 inhibition improves GIST survival
Nature Reviews Clinical Oncology, Published online: 24 June 2022; doi:10.1038/s41571-022-00659-5HSP90 inhibition improves GIST survival (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 24, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
From ASCO 2022
Nature Reviews Clinical Oncology, Published online: 24 June 2022; doi:10.1038/s41571-022-00656-8From ASCO 2022 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 24, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Dostarlimab effective in dMMR LARC
Nature Reviews Clinical Oncology, Published online: 24 June 2022; doi:10.1038/s41571-022-00661-xDostarlimab effective in dMMR LARC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 24, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome
Nature Reviews Clinical Oncology, Published online: 23 June 2022; doi:10.1038/s41571-022-00645-xLiquid biopsy assays of diverse cancer-associated molecular alterations in blood, including genomic, epigenomic, transcriptomic, proteomic and metabolomics changes, offer considerable opportunities for early detection of cancer as well as improved management of the disease. In this Perspective, the authors review key advances in liquid biopsy-based multi-omics approaches for biomarker discovery. They also introduce the ‘nano-omics’ paradigm, whereby nanotechnology tools are used to capture and enrich various cancer-derived a...
Source: Nature Reviews Clinical Oncology - June 23, 2022 Category: Cancer & Oncology Authors: Lois Gardner Kostas Kostarelos Parag Mallick Caroline Dive Marilena Hadjidemetriou Source Type: research
Radiotheranostics in oncology: current challenges and emerging opportunities
Nature Reviews Clinical Oncology, Published online: 20 June 2022; doi:10.1038/s41571-022-00652-yRadiotheranostics enables the clinician to image and then target lesions using the same probe. Despite this appealing potential, interest in the field of radiotheranostics has long been constrained by a lack of expertise, high infrastructure costs and the availability of non-radioactive alternative approaches. Nonetheless, several recent successes have led to renewed research interest. In this Review, the authors summarize the current challenges and opportunities in this rapidly emerging area. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 20, 2022 Category: Cancer & Oncology Authors: Lisa Bodei Ken Herrmann Heiko Sch öder Andrew M. Scott Jason S. Lewis Source Type: research
Improving outcomes demands patient-centred interventions and equitable delivery
Nature Reviews Clinical Oncology, Published online: 01 June 2022; doi:10.1038/s41571-022-00653-xA recent study not only confirms mounting evidence that technology-facilitated symptom monitoring improves care and should be considered for all patients with cancer, but also suggests that patient navigators can help to deliver such interventions. Herein we discuss how such an approach can minimize disparities and maximize access to culturally appropriate patient-centred care. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - June 1, 2022 Category: Cancer & Oncology Authors: Gabrielle B. Rocque Abby R. Rosenberg Source Type: research
New CAPSTONE of SCLC therapy?
Nature Reviews Clinical Oncology, Published online: 31 May 2022; doi:10.1038/s41571-022-00654-wNew CAPSTONE of SCLC therapy? (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 31, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Advancing therapy for neuroblastoma
Nature Reviews Clinical Oncology, Published online: 25 May 2022; doi:10.1038/s41571-022-00643-zNeuroblastomas are tumours of sympathetic origins typically seen in infants (≤5 years of age). In this Review, the authors describe progress in the treatment of patients with neuroblastoma, which has resulted in considerable improvements in survival outcomes over the past several decades. The authors then summarize ongoing attempts to personalize therapy in patients with high-risk disease, and to safely de-escalate therapy in those with low-risk disease. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 25, 2022 Category: Cancer & Oncology Authors: Bo Qiu Katherine K. Matthay Source Type: research
Combination improves salvage outcomes
Nature Reviews Clinical Oncology, Published online: 23 May 2022; doi:10.1038/s41571-022-00651-zCombination improves salvage outcomes (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 23, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Tiragolumab active in PD-L1+ NSCLC
Nature Reviews Clinical Oncology, Published online: 23 May 2022; doi:10.1038/s41571-022-00650-0Tiragolumab active in PD-L1+ NSCLC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 23, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
